Longterm renal outcome after 10 years enzyme replacement therapy with agalsidase A in Fabry male patients

被引：0
|
作者：
Karabul, Nesrin [1 ]
Arash, Laila [1 ]
Waechter, Maike [1 ]
Beck, Michael [1 ]
Kampmann, Christof [1 ]
Mengel, Eugen [1 ]
机构：
[1] Villa Metabol, Mainz, Germany
来源：
MOLECULAR GENETICS AND METABOLISM | 2014年 / 111卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2013.12.130
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
118
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [21] Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment (vol 10, 125, 2015)
    Kampmann, Christoph
    Perrin, Amandine
    Beck, Michael
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [22] SWITCH FROM AGALSIDASE BETA TO AGALSIDASE ALFA IN THE ENZYME REPLACEMENT THERAPY OF PATIENTS WITH FABRY DISEASE IN LATIN AMERICA
    Ripeau, Diego
    Amartino, Hernan
    Cedrolla, Martin
    Urtiaga, Luis
    Urdaneta, Bella
    Cano, Marilis
    Valdez, Rita
    Antongiovanni, Norberto
    Masllorens, Francisca
    MEDICINA-BUENOS AIRES, 2017, 77 (03) : 173 - 179
  • [23] RENAL AND CARDIAC PATHOLOGY IN FABRY DISEASE AFTER 13 YEARS ON ENZYME REPLACEMENT THERAPY
    Talbot, A.
    Finlay, M.
    Nicholls, K.
    NEPHROLOGY, 2015, 20 : 31 - 31
  • [24] SAFETY OF ENZYME REPLACEMENT THERAPY WITH AGALSIDASE ALFA IN CHILDREN WITH FABRY DISEASE
    Ramaswami, U.
    Wendt, S.
    Parini, R.
    Pintos, G.
    Leon, J. A.
    Santus, F.
    Whybra, C.
    Beck, M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 167 - 167
  • [25] FABRY NEPHROPATHY (FN) OUTCOME AND THE IMPACT OF DIAGNOSTIC KIDNEY BIOPSIES AFTER 10 YEARS ENZYME REPLACEMENT THERAPY (ERT)
    Skrunes, R.
    Larsen, K. K.
    Svarstad, E.
    Tondel, C.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 154 - 155
  • [26] Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease
    Ries, Markus
    Clarke, Joe T. R.
    Whybra, Catharina
    Timmons, Margaret
    Robinson, Chevalia
    Schlaggar, Bradley L.
    Pastores, Gregory
    Lien, Y. Howard
    Kampmann, Christoph
    Brady, Roscoe O.
    Beck, Michael
    Schiffmann, Raphael
    PEDIATRICS, 2006, 118 (03) : 924 - 932
  • [27] Fabry disease in children: agalsidase-beta enzyme replacement therapy
    Borgwardt, L.
    Feldt-Rasmussen, U.
    Rasmussen, A. K.
    Ballegaard, M.
    Lund, A. Meldgaard
    CLINICAL GENETICS, 2013, 83 (05) : 432 - 438
  • [28] The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease
    Morell, Chantal F.
    Clarke, Joe T. R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (05) : 631 - 639
  • [29] Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease
    Kalkum, G.
    Macchiella, D.
    Reinke, J.
    Koelbl, H.
    Beck, M.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 144 (01) : 92 - 93
  • [30] Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10-Year Fabry Outcome Survey (FOS) Analysis
    Ramaswami, Uma
    Beck, Michael
    Hughes, Derralynn
    Kampmann, Christoph
    Botha, Jaco
    Pintos-Morell, Guillem
    West, Michael L.
    Niu, Dau-Ming
    Nicholls, Kathy
    Giugliani, Roberto
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 3705 - 3715
12345